Embodiments of the invention include compositions and methods related to replicative oncolytic rhabdoviruses pseudotyped with an arenavirus glycoprotein and their use as anti-cancer therapeutics particularly in combination with complement inhibitors.

Embodiments of the invention include compositions and methods related to replicative oncolytic rhabdoviruses pseudotyped with an arenavirus glycoprotein and their use as anti-cancer therapeutics particularly in combination with complement inhibitors.

A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.

A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.

Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.

Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.

Separation media includes a support substrate and a plurality of separation ligands immobilized on the support substrate. The plurality of separation ligands include an affinity group capable of binding to a carbohydrate. Methods of making the separation media and methods of using the separation media are disclosed.

Separation media includes a support substrate and a plurality of separation ligands immobilized on the support substrate. The plurality of separation ligands include an affinity group capable of binding to a carbohydrate. Methods of making the separation media and methods of using the separation media are disclosed.

An antiviral peptide provided by the present invention includes: (1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).

An antiviral peptide provided by the present invention includes: (1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).